The Latin America, Middle East and Africa Body Fluid Collection And Diagnostics Market would witness market growth of 10.4% CAGR during the forecast period (2022-2028).
The therapeutic screening and health evaluation are also done by testing body fluid. A number of medical decisions depends on the results gathered by the examination of the body fluid in a clinical laboratory. Therefore, the clinical laboratory has the responsibility to provide authentic data for the identification, diagnosis, prognosis, treatment, and prevention of human disease.
It is highly necessary that the clinical laboratory is adequately equipped with the latest and most reliable analytical methodology to examine chemical species in biological fluids. The physicians use body fluid cellular diagnosis to get necessary information about the patient’s health conditions, along with inflammatory diseases, hemorrhage, infection, and malignancy.
Earlier, body fluid analysis was conducted manually with an optical microscope, which is remarked as a gold standard method for counting cells. Manual evaluation requires a significant time to be spent on it, and is labor intensive. A load of body fluid diagnosis only rises with increasing pressure and less resource availability.
The UAE government has made developing a top-notch healthcare infrastructure as a primary priority; as a result, the industry has developed and grown tremendously over the past few years. The populations with relatively high levels of income will seek higher quality healthcare as the prevalence of lifestyle diseases rises. To meet this demand, the government is concentrating on building healthcare infrastructure. In order to make Dubai a regional hub of superior healthcare, the UAE government intends to increase the number of medical tourists visiting the country. Better surgical and diagnostics facilities are being offered as a result of the region’s focus on boosting medical tourism and providing the best healthcare facilities available. All these elements are predicted to support the market expansion in LAMEA region.
The Brazil market dominated the LAMEA Body Fluid Collection and Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $779.7 million by 2028. The Argentina market is experiencing a CAGR of 11% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.1% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
The therapeutic screening and health evaluation are also done by testing body fluid. A number of medical decisions depends on the results gathered by the examination of the body fluid in a clinical laboratory. Therefore, the clinical laboratory has the responsibility to provide authentic data for the identification, diagnosis, prognosis, treatment, and prevention of human disease.
It is highly necessary that the clinical laboratory is adequately equipped with the latest and most reliable analytical methodology to examine chemical species in biological fluids. The physicians use body fluid cellular diagnosis to get necessary information about the patient’s health conditions, along with inflammatory diseases, hemorrhage, infection, and malignancy.
Earlier, body fluid analysis was conducted manually with an optical microscope, which is remarked as a gold standard method for counting cells. Manual evaluation requires a significant time to be spent on it, and is labor intensive. A load of body fluid diagnosis only rises with increasing pressure and less resource availability.
The UAE government has made developing a top-notch healthcare infrastructure as a primary priority; as a result, the industry has developed and grown tremendously over the past few years. The populations with relatively high levels of income will seek higher quality healthcare as the prevalence of lifestyle diseases rises. To meet this demand, the government is concentrating on building healthcare infrastructure. In order to make Dubai a regional hub of superior healthcare, the UAE government intends to increase the number of medical tourists visiting the country. Better surgical and diagnostics facilities are being offered as a result of the region’s focus on boosting medical tourism and providing the best healthcare facilities available. All these elements are predicted to support the market expansion in LAMEA region.
The Brazil market dominated the LAMEA Body Fluid Collection and Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $779.7 million by 2028. The Argentina market is experiencing a CAGR of 11% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.1% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Kits & Consumables
- Instruments
- Tests/Services
By Technology
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Fluorescence in situ hybridization (FISH)
- Others
By Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
By Application
- Diagnostics & Monitoring
- Therapeutic Decision Making
- Prognostics & Screening
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Bio-Rad Laboratories, Inc
- Illumina, Inc
- Qiagen N.V
- Johnson & Johnson
- F.Hoffmann-La Roche Ltd
- Laboratory Corporation of America Holdings
- Biocept, Inc
- MDxHealth SA
- Guardant Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Body Fluid Collection And Diagnostics Market, by Product
1.4.2 LAMEA Body Fluid Collection And Diagnostics Market, by Technology
1.4.3 LAMEA Body Fluid Collection And Diagnostics Market, by Sample Type
1.4.4 LAMEA Body Fluid Collection And Diagnostics Market, by Application
1.4.5 LAMEA Body Fluid Collection And Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2021, Jan - 2022, Sep) Leading Players
Chapter 4. LAMEA Body Fluid Collection And Diagnostics Market by Product
4.1 LAMEA Kits & Consumables Market by Country
4.2 LAMEA Instruments Market by Country
4.3 LAMEA Tests/Services Market by Country
Chapter 5. LAMEA Body Fluid Collection And Diagnostics Market by Technology
5.1 LAMEA Polymerase Chain Reaction (PCR) Market by Country
5.2 LAMEA Next Generation Sequencing (NGS) Market by Country
5.3 LAMEA Fluorescence in situ hybridization (FISH) Market by Country
5.4 LAMEA Others Market by Country
Chapter 6. LAMEA Body Fluid Collection And Diagnostics Market by Sample Type
6.1 LAMEA Blood Market by Country
6.2 LAMEA Urine Market by Country
6.3 LAMEA Saliva Market by Country
6.4 LAMEA Cerebrospinal Fluid Market by Country
Chapter 7. LAMEA Body Fluid Collection And Diagnostics Market by Application
7.1 LAMEA Diagnostics & Monitoring Market by Country
7.2 LAMEA Therapeutic Decision Making Market by Country
7.3 LAMEA Prognostics & Screening Market by Country
Chapter 8. LAMEA Body Fluid Collection And Diagnostics Market by Country
8.1 Brazil Body Fluid Collection And Diagnostics Market
8.1.1 Brazil Body Fluid Collection And Diagnostics Market by Product
8.1.2 Brazil Body Fluid Collection And Diagnostics Market by Technology
8.1.3 Brazil Body Fluid Collection And Diagnostics Market by Sample Type
8.1.4 Brazil Body Fluid Collection And Diagnostics Market by Application
8.2 Argentina Body Fluid Collection And Diagnostics Market
8.2.1 Argentina Body Fluid Collection And Diagnostics Market by Product
8.2.2 Argentina Body Fluid Collection And Diagnostics Market by Technology
8.2.3 Argentina Body Fluid Collection And Diagnostics Market by Sample Type
8.2.4 Argentina Body Fluid Collection And Diagnostics Market by Application
8.3 UAE Body Fluid Collection And Diagnostics Market
8.3.1 UAE Body Fluid Collection And Diagnostics Market by Product
8.3.2 UAE Body Fluid Collection And Diagnostics Market by Technology
8.3.3 UAE Body Fluid Collection And Diagnostics Market by Sample Type
8.3.4 UAE Body Fluid Collection And Diagnostics Market by Application
8.4 Saudi Arabia Body Fluid Collection And Diagnostics Market
8.4.1 Saudi Arabia Body Fluid Collection And Diagnostics Market by Product
8.4.2 Saudi Arabia Body Fluid Collection And Diagnostics Market by Technology
8.4.3 Saudi Arabia Body Fluid Collection And Diagnostics Market by Sample Type
8.4.4 Saudi Arabia Body Fluid Collection And Diagnostics Market by Application
8.5 South Africa Body Fluid Collection And Diagnostics Market
8.5.1 South Africa Body Fluid Collection And Diagnostics Market by Product
8.5.2 South Africa Body Fluid Collection And Diagnostics Market by Technology
8.5.3 South Africa Body Fluid Collection And Diagnostics Market by Sample Type
8.5.4 South Africa Body Fluid Collection And Diagnostics Market by Application
8.6 Nigeria Body Fluid Collection And Diagnostics Market
8.6.1 Nigeria Body Fluid Collection And Diagnostics Market by Product
8.6.2 Nigeria Body Fluid Collection And Diagnostics Market by Technology
8.6.3 Nigeria Body Fluid Collection And Diagnostics Market by Sample Type
8.6.4 Nigeria Body Fluid Collection And Diagnostics Market by Application
8.7 Rest of LAMEA Body Fluid Collection And Diagnostics Market
8.7.1 Rest of LAMEA Body Fluid Collection And Diagnostics Market by Product
8.7.2 Rest of LAMEA Body Fluid Collection And Diagnostics Market by Technology
8.7.3 Rest of LAMEA Body Fluid Collection And Diagnostics Market by Sample Type
8.7.4 Rest of LAMEA Body Fluid Collection And Diagnostics Market by Application
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Acquisition and Mergers:
9.2 Guardant Health, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.5.3 Acquisition and Mergers:
9.3 Illumina, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisition and Mergers:
9.4 Qiagen N.V.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisition and Mergers:
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.5.2 Product Launches and Product Expansions:
9.6 F. Hoffmann-La Roche Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Product Launches and Product Expansions:
9.7 Laboratory Corporation of America Holdings
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental Analysis
9.7.4 Recent strategies and developments:
9.7.4.1 Partnerships, Collaborations, and Agreements:
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.9 Biocept, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Product Launches and Product Expansions:
9.10. MDxHealth SA
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- Biocept, Inc.
- MDxHealth SA
- Guardant Health, Inc.
Methodology
LOADING...